Original ResearchFull Report: Clinical—Alimentary TractEndoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn’s Disease
Keywords
Abbreviations used in this paper
Cited by (0)
Conflicts of interest The authors disclose the following: Silvio Danese reports consultancy fees from AbbVie, Allergan, Amgen, AstraZeneca, Biogen, Boehringer Ingelheim, Celgene, Celltrion, Ferring Pharmaceuticals Inc., Gilead, Hospira, Janssen, Johnson & Johnson, MSD, Mundipharma, Pfizer, Roche, Sandoz, Takeda, TiGenix, UCB, and Vifor. William Sandborn reports consulting fees from University of Western Ontario (owner of Robarts Clinical Trials, Inc), AbbVie, Akros Pharma, Allergan, Ambrx, Amgen, Ardelyx, Arena Pharmaceuticals, Atlantic Pharmaceuticals, Avaxia, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Conatus, Cosmo Technologies, Escalier Biosciences, Ferring, Ferring Research Institute, Forward Pharma, Galapagos, Genentech, Gilead Sciences, Immune Pharmaceuticals, Index Pharmaceuticals, Janssen, Kyowa Hakko Kirin Pharma, Lilly, Medimmune, Mesoblast, Miraca Life Sciences, Nivalis Therapeutics, Novartis, Nutrition Science Partners, Oppilan Pharma, Otsuka, Palatin, Paul Hastings, Pfizer, Precision IBD, Progenity, Prometheus Laboratories, Qu Biologics, Regeneron, Ritter Pharmaceuticals, Robarts Clinical Trials, Salix, Seattle Genetics, Seres Therapeutics, Shire, Sigmoid Biotechnologies, Takeda, Theradiag, Theravance, TiGenix, Tillotts Pharma, UCB Pharma, Vascular Biogenics, and Vivelix; research grants from Atlantic Healthcare Limited, Amgen, Genentech, Gilead Sciences, AbbVie, Janssen, Takeda, Lilly, and Celgene/Receptos; payments for lectures/speakers bureau from AbbVie, Janssen, and Takeda; and holds stock/stock options in Escalier Biosciences, Oppilan Pharma, Precision IBD, Progenity, and Ritter Pharmaceuticals. Brian Feagan has received consulting fees from Abbott/AbbVie, Actogenix, Akros, Albireo Pharma, Allergan, Amgen, AstraZeneca, Atlantic Pharma, Avaxia Biologics, Avir Pharma, Baxter Healthcare Corp., Biogen Idec, Boehringer Ingelheim, Bristol-Myers Squibb, Calypso Biotech, Celgene, Elan/Biogen, EnGene, Ferring Pharma, Roche/Genentech, Galapagos, GiCare Pharma, Gilead, Given Imaging Inc., GlaxoSmithKline, Inception IBD, Ironwood Pharma, Janssen Biotech (Centocor), J&J/Janssen, Kyowa Kakko Kirin, Lexicon, Lilly, Lycera BioTech, Merck, Mesoblast Pharma, Millennium, Nektar, Nestles, Novo Nordisk, Pfizer, Prometheus Therapeutics and Diagnostics, Protagonist, Receptos, Roche/Genentech, Salix Pharma, Serono, Shire, Sigmoid Pharma, Synergy Pharma Inc., Takeda, Teva Pharma, TiGenix, Tillotts, UCB Pharma, Vertex Pharma, Vivelix Pharma, VHsquared Ltd., Warner-Chilcott, Wyeth, Zealand, and Zyngenia; grant/research support from AbbVie, Amgen, AstraZeneca/MedImmune, Atlantic Pharmaceuticals, Boehringer Ingelheim, Celgene Corporation, Celltech, Genentech/Hoffmann-La Roche, Gilead Sciences, GlaxoSmithKline, Janssen Research & Development, Pfizer, Receptos/Celgene International, Sanofi, Santarus, Takeda, Tillotts Pharma, and UCB; served as a Scientific Advisory Board member for Abbott/AbbVie, Allergan, Amgen, AstraZeneca, Atlantic Pharma, Avaxia Biologics, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Centocor, Elan/Biogen, Ferring, Galapagos, Genentech/Roche, J&J/Janssen, Merck, Nestles, Novartis, Novo Nordisk, Pfizer, Prometheus Laboratories, Protagonist, Salix Pharma, Takeda, Teva, TiGenix, Tillotts Pharma, and UCB Pharma; has been on the Speakers Bureau for Abbott/AbbVie, J&J/Janssen, Lilly, Takeda, Tillotts, and UCB Pharma; and is Senior Scientific Officer for Robarts Clinical Trials Inc. Jean-Frédéric Colombel reports receiving research grants from AbbVie, Janssen Pharmaceuticals and Takeda; receiving payment for lectures from AbbVie, Amgen, Allergan, Ferring Pharmaceuticals, Shire, and Takeda; receiving consulting fees from AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, Celgene Corporation, Celltrion, Eli Lilly, Enterome, Ferring Pharmaceuticals, Genentech, Janssen Pharmaceuticals, Landos, Ipsen, Medimmune, Merck, Novartis, Pfizer, Shire, Takeda, and TiGenix; and holding stock options in Intestinal Biotech Development and Genfit. Séverine Vermeire reports research support from Merck, AbbVie, Pfizer, Takeda, and Janssen; consultancy fees from AbbVie, MSD, Prometheus Laboratories, Tillotts Pharma, Eli Lilly, Pfizer, Takeda, Janssen, Celgene, Ferring Pharmaceuticals, Galapagos, Gilead, Hospira, MundiPharma, Second Genome, Biogen; and payments for lectures/speakers bureau from AbbVie, Pfizer, Takeda, Janssen, Ferring Pharmaceuticals, Galapagos, and Hospira. Sarah Glover reports research support from Celgene, AbbVie, Pfizer, Shire, USB, Genentech, Takeda, and Janssen; consultancy fees from AbbVie, Pfizer, Takeda, and Janssen; and payments for lectures/speakers bureau from AbbVie, Takeda, and Janssen. Jordi Rimola reports consultancy fees from Robarts Clinical Trials, Takeda, and TiGenix; grant/research support from AbbVie and Genentech; and speaker/honoraria fees from AbbVie, MSD, Janssen, and Takeda. Jenifer Siegelman and Jeffrey Bornstein are employees of Takeda. Stephen Jones is an external consultant for Takeda.
Funding This study was sponsored by Takeda Development Center Americas, Inc., Deerfield, IL. Medical writing assistance was provided by David Peters and Julia Saiz, PhD, of Syneos Health, and funded by Takeda.
Author names in bold designate shared co-first authorship.